Effect of Local Pamidronate in Preventing Bone Loss After Total Hip Arthroplasty

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00548288
Recruitment Status : Unknown
Verified October 2007 by General and Teaching Hospital Celje.
Recruitment status was:  Not yet recruiting
First Posted : October 23, 2007
Last Update Posted : October 23, 2007
Information provided by:
General and Teaching Hospital Celje

Brief Summary:
The aims of the study are to determine whether pamidronate applied locally causes diminished periprosthetic bone loss and decreased rate of bone turnover compared to patients receiving placebo after cemented total hip arthroplasty (THA). The study design will be prospective, randomized, and blind. Periprosthetic bone mineral density (BMD) will be measured with dual energy X-ray absorptiometry (DXA) at the total periprosthetic area as well as at seven Gruen zones or regions of interest. DXA scans will be performed at one week (baseline), three months, and six months postoperatively. Mean values of biochemical markers of bone turnover, BMD, and baseline-normalized BMD values will be compared between the bisphosphonate and placebo groups at each time point. For all temporal measurements including bone markers, BMD and normalized BMD, mean values will be compared across each time point within a given group.

Condition or disease Intervention/treatment Phase
Arthroplasty Mineral Density Drug: pamidronate Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Phase 1 Study of the Effect of Local Pamidronate Application in Preventing Periprosthetic Bone Loss After Total Cemented Hip Arthroplasty
Study Start Date : November 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Minerals
U.S. FDA Resources

Primary Outcome Measures :
  1. Periprosthetic bone mineral density [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Biochemical markers of bone turnover [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   50 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patients with hip arthritis scheduled for total cemented hip arthroplasty

Exclusion Criteria:

  • pregnancy
  • endoprosthesis on contralateral hip

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00548288

Contact: Samo K Fokter, MD, PhD +38634233306

Department for Orthopaedic Surgery and Sports Trauma, Celje Teaching Hospital Not yet recruiting
Celje, Slovenia, 3000
Sponsors and Collaborators
General and Teaching Hospital Celje
Principal Investigator: Samo K Fokter, MD, PhD General and Teaching Hospital Celje Identifier: NCT00548288     History of Changes
Other Study ID Numbers: PAM19382CE
First Posted: October 23, 2007    Key Record Dates
Last Update Posted: October 23, 2007
Last Verified: October 2007